Estimation of TIMP-2 in Patients with Chronic Kidney Disease

Abstract

Background: Chronic kidney disease (CKD) is a progressive condition with high morbidity and mortality, often associated with hypertension and diabetes. Early detection is essential for effective management. TIMP-2 has shown promise as a biomarker due to its role in extracellular matrix regulation and renal fibrosis, potentially offering benefits over traditional kidney function markers.

Objective: Estimating TIMP-2 levels in patients with chronic kidney disease and assessing its correlation with clinical and demographic factors.

Methods: A case-control study was conducted involving 90 participants individuals aged 30–70 years were enrolled, including 60 CKD patients (30 dialysis and 30 pre-dialysis stages) and 30 age- and sex-matched healthy controls. Serum levels of TIMP-2 were, creatinine, and (eGFR) were assessed.

Results: TIMP-2 levels were significantly elevated in CKD patients compared to healthy controls with a stepwise increase across disease stages. Dialysis patients exhibited the highest concentrations. TIMP-2 was significantly associated with declining renal function, correlating with elevated creatinine and reduced eGFR. While TIMP-2 levels showed no significant differences by age, sex, BMI, or hypertension, they were markedly higher in diabetic patients.

Conclusion: TIMP-2 shows strong potential as a biomarker for detecting and monitoring CKD, particularly in advanced stages. Its progressive increase across CKD severity and its association with renal function support its use in disease assessment. Further research may establish its clinical utility.